摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 3-[(2-bromophenyl)oxy]azetidine-1-carboxylate | 960492-72-2

中文名称
——
中文别名
——
英文名称
tert-butyl 3-[(2-bromophenyl)oxy]azetidine-1-carboxylate
英文别名
tert-butyl 3-(2-bromophenoxy)azetidine-1-carboxylate
tert-butyl 3-[(2-bromophenyl)oxy]azetidine-1-carboxylate化学式
CAS
960492-72-2
化学式
C14H18BrNO3
mdl
——
分子量
328.206
InChiKey
UTTUBKVBPYKOTE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    383.8±32.0 °C(predicted)
  • 密度:
    1.397±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    38.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
    申请人:Isabel Elise
    公开号:US20090170828A1
    公开(公告)日:2009-07-02
    Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)
    结构式I的氮杂环丙烷衍生物是选择性抑制硬脂酰辅酶A delta-9去饱和酶(SCD1)的化合物,相对于其他已知的硬脂酰辅酶A去饱和酶。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病,包括心血管疾病;动脉粥样硬化;肥胖症;糖尿病;神经系统疾病;代谢综合征;胰岛素抵抗;肝脂肪变性和非酒精性脂肪性肝炎。
  • Ortho-C–H methoxylation of aryl halides enabled by a polarity-reversed N–O reagent
    作者:Xin Liu、Yue Fu、Zhijie Chen、Peng Liu、Guangbin Dong
    DOI:10.1038/s41557-023-01312-z
    日期:2023.10
    prefunctionalized substrates to control site-selectivity. While palladium/norbornene cooperative catalysis is promising for site-specific arene vicinal difunctionalization through simultaneous reactions with an electrophile and a nucleophile, the electrophile scope has been limited to species based on relatively ‘soft’ elements, such as carbon, nitrogen and sulfur. Here we report the development of an ortho
    氧取代芳烃广泛存在于具有生物学重要性的分子中,可以用作安装其他官能团的多功能手柄。然而,氧基团直接和位点选择性地安装到常见的芳香族化合物上仍然具有挑战性,尤其是当同时需要额外的芳烃官能化时。当前的芳烃 C-H 氧化策略通常需要定向基团或精确预官能化的底物来控制位点选择性。虽然钯/降冰片烯协同催化有望通过与亲电试剂和亲核试剂同时反应实现位点特异性芳烃附近的双功能化,但亲电范围仅限于基于相对“软”元素(如碳、氮和硫)的物种。在这里,我们报道了与普通芳基卤化物的邻位氧化反应的发展,以快速递送不同的芳基醚。“硬”氧亲电试剂的偶联由稳定的、极性反转的、构象预扭曲的 N-O 试剂实现,并由 C7-溴取代的降冰片烯介质促进。机理研究揭示了作为亲氧试剂的 N-O 试剂与富电子 Pd(II) 亲核试剂之间的独特 SN2 型途径。
  • Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors
    作者:Elise Isabel、David A. Powell、W. Cameron Black、Chi-Chung Chan、Sheldon Crane、Robert Gordon、Jocelyne Guay、Sebastien Guiral、Zheng Huang、Joël Robichaud、Kathryn Skorey、Paul Tawa、Lijing Xu、Lei Zhang、Renata Oballa
    DOI:10.1016/j.bmcl.2010.10.107
    日期:2011.1
    Potent and orally bioavailable SCD inhibitors built on an azetidinyl pyridazine scaffold were identified. In a one-month gDIO mouse model of obesity, we demonstrated that there was no therapeutic index even at low doses; efficacy in preventing weight gain tracked closely with skin and eye adverse events. This was attributed to the local SCD inhibition in these tissues as a consequence of the broad tissue distribution observed in mice for this class of compounds. The search for new structural scaffolds which may display a different tissue distribution was initiated. In preparation for an HTS campaign, a radiolabeled azetidinyl pyridazine displaying low non-specific binding in the scintillation proximity assay was prepared. (c) 2010 Elsevier Ltd. All rights reserved.
  • EP2032566A4
    申请人:——
    公开号:EP2032566A4
    公开(公告)日:2009-07-08
  • AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
    申请人:Merck Frosst Canada Ltd.
    公开号:EP2032566A1
    公开(公告)日:2009-03-11
查看更多